Registry with evaluation and genetic information of patients with advanced sarcoidosis and matched sarcoidosis

Inclusion criteria

• Patients with diagnosis of sarcoidosis based on ATS/WASOG criteria 22
• Age ≥ 18 years.
• Life expectancy of at least 2 years.
• Pulmonary function tests (spirometry) within one month of entry or willing to under pulmonary function testing on the day of study enrollment
• Sarcoidosis as characterized as either advanced or non-advanced (see protocol for definition of advanced disease)
• Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion criteria

• Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator
• Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
• Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.

Advanced sarcoidosis is defined by the presence of one or more of the following features:

1. Advanced pulmonary disease as defined by one or more of the following
2. Symptomatic cardiac disease due to sarcoidosis by either MRI or PET scanning and
3. Symptomatic neurologic disease
4. Patients who have received third line therapy (anti-TNF antibodies, rituximab, or RCI)